Scarica l'app Stockscreener
10.97
0.99%
-0.11
Dopo l'orario di chiusura:
10.97
Immunome Inc Borsa (IMNM) Ultime notizie
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from Analysts - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Wellington Management Group LLP - Defense World
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short Interest - Defense World
Immunome, Inc. (NASDAQ:IMNM) Short Interest Update - MarketBeat
Long Term Trading Analysis for (IMNM) - Stock Traders Daily
Immunome, Inc. (NASDAQ:IMNM) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome: A Recently Acquired Lead Asset And A Small Market (NASDAQ:IMNM) - Seeking Alpha
The Manufacturers Life Insurance Company Sells 1,437 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Intech Investment Management LLC Takes $219,000 Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Janus Henderson Group PLC Purchases 324,614 Shares of Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Cerity Partners LLC Has $776,000 Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Where are the Opportunities in (IMNM) - Stock Traders Daily
Immunome Grants Stock Options to 15 New Hires in Workforce Expansion - StockTitan
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - The Bakersfield Californian
President of Immunome Picks Up 24% More Stock - Simply Wall St
Why Is Immunome Inc (NASDAQ: IMNM) Gaining? - Stocks Register
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts - Defense World
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - Defense World
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock - Investing.com India
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock By Investing.com - Investing.com Australia
Immunome Inc (IMNM) CEO Clay Siegall Increases Stake with Signif - GuruFocus.com
Insider Buying: Robert Lechleider Acquires Shares of Immunome In - GuruFocus.com
Immunome, Inc. (NASDAQ:IMNM) CTO Acquires $198,030.00 in Stock - MarketBeat
Insider Buying: Immunome, Inc. (NASDAQ:IMNM) CEO Purchases 66,057 Shares of Stock - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Insider Acquires $149,831.40 in Stock - MarketBeat
Philip Tsai, CTO of Immunome, buys $198,030 in company stock By Investing.com - Investing.com South Africa
Philip Tsai, CTO of Immunome, buys $198,030 in company stock - Investing.com India
Immunome CEO Clay Siegall acquires $962,181 in company stock By Investing.com - Investing.com Nigeria
Immunome CEO Clay Siegall acquires $962,181 in company stock - Investing.com India
(IMNM) Investment Analysis and Advice - Stock Traders Daily
Immunome files to sell 1.8M shares of common stock for holders - TipRanks
Victory Capital Management Inc. Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Victory Capital Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Leerink Partnrs Decreases Earnings Estimates for Immunome - MarketBeat
Wedbush Has Bullish Outlook for Immunome FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for Immunome Lowered by Leerink Partnrs - Defense World
Immunome Inc. Announces Third Quarter 2024 Financial Results and Pipeline Progress - Defense World
Stephens & Co. Initiates Coverage of Immunome (IMNM) with Overweight Recommendation - MSN
Immunome Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Immunome (NASDAQ:IMNM) Stock Price Down 7% After Analyst Downgrade - Defense World
T. Rowe Price Investment Management, Inc. Expands Stake in Immun - GuruFocus.com
Piper Sandler maintains overweight on IMNM with $21 target By Investing.com - Investing.com Canada
Piper Sandler maintains overweight on IMNM with $21 target - Investing.com India
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - BioSpace
Janus Henderson Group's Strategic Acquisition of Immunome Inc Sh - GuruFocus.com
Immunome (NASDAQ:IMNM) Shares Down 7% Following Analyst Downgrade - MarketBeat
Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $21.00 - MarketBeat
Immunome price target lowered to $21 from $23 at Piper Sandler - TipRanks
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):